Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ono-2952. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ono-2952 SCHEMBL29613010 | 1.00 | MAPT (0.39) | MAPTKIF11ABCB1ABCG2TUBB4A | |
| Ono-2952 SCHEMBL31518699 | 1.00 | MAPT (0.39) | MAPTKIF11ABCB1ABCG2TUBB4A | |
| Ono-2952 SCHEMBL2032485 | 1.00 | MAPT (0.39) | MAPTKIF11ABCB1ABCG2TUBB4A | |
| SCHEMBL2030005 | 0.93 | KIF11 (0.42) | MAPTKIF11ABCB1ABCG2MAPKAPK2 | |
| SCHEMBL2033031 | 0.91 | KIF11 (0.36) | MAPTKIF11ABCB1ABCG2POLB | |
| SCHEMBL2030011 | 0.91 | KIF11 (0.39) | MAPTKIF11ABCB1ABCG2TUBB4A | |
| SCHEMBL2032028 | 0.91 | MAPKAPK2 (0.37) | MAPTABCB1ABCG2TUBB4ATUBB | |
| SCHEMBL2030868 | 0.90 | KIF11 (0.34) | MAPTKIF11ABCB1ABCG2ATM | |
| SCHEMBL2036072 | 0.90 | KIF11 (0.39) | MAPTKIF11ABCB1ABCG2MAPKAPK2 | |
| SCHEMBL2031298 | 0.90 | MAPT (0.38) | MAPTKIF11ABCB1ABCG2TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675275-B2 | Prophylactic and/or therapeutic agent for fibromyalgia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | claimed |
| EP-3243514-B1 | PREVENTION AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | ONO PHARMACEUTICAL CO (JP) | 2020-02-19 | — | — | EP | claimed |
| US-20180169077-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | claimed |
| EP-3243514-A1 | PREVENTION AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | ONO Pharmaceutical Co., Ltd. (JP) | 2017-11-15 | — | — | EP | claimed |
| US-20170119742-A1 | MEDICAMENT FOR PREVENTING AND/OR TREATING STRESS DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-04 | — | — | US | claimed |
| EP-3156054-A1 | MEDICINE FOR PREVENTING AND/OR TREATING STRESS-INDUCED DISEASES | ONO Pharmaceutical Co., Ltd. (JP) | 2017-04-19 | — | — | EP | claimed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | claimed |
| US-8476293-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | claimed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | claimed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | claimed |
| US-10675275-B2 | Prophylactic and/or therapeutic agent for fibromyalgia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-10675275-B2 | Prophylactic and/or therapeutic agent for fibromyalgia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-10675275-B2 | Prophylactic and/or therapeutic agent for fibromyalgia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| EP-3243514-B1 | PREVENTION AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | ONO PHARMACEUTICAL CO (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3243514-B1 | PREVENTION AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | ONO PHARMACEUTICAL CO (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | MAPT 2331/4885KIF11 4657/4885ABCB1 90/4885 |
| US-20170119742-A1 | MEDICAMENT FOR PREVENTING AND/OR TREATING STRESS DISEASES | TSPO, CNR1, CNR2 | MAPT 1012/4885KIF11 3948/4885ABCB1 593/4885 |
| US-20180169077-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA | TSPO, CNR2, CNR1 | MAPT 3087/4885KIF11 3230/4885ABCB1 1078/4885 |
| US-10675275-B2 | Prophylactic and/or therapeutic agent for fibromyalgia | TSPO, CNR2, CNR1 | MAPT 3087/4885KIF11 3230/4885ABCB1 1078/4885 |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | SI, ALPI, SLC10A2 | MAPT 2402/4885KIF11 4674/4885ABCB1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.